has unlawfully denied its plan to pay rebates to qualifying organisations who source Eliquis only after they have bought the drug at normal commercial prices. In court documents, BMS' counsel ...

Factor XI blockers have produced mixed results so far in testing, however. Even if approved, they could face commercial ...

(Bloomberg) -- Bristol Myers Squibb Co. raised its 2024 earnings guidance after reporting better-than-expected revenue and ...